Introduction 32 Many low income countries soon will need to consider whether to continue pneumococcal 33 conjugate vaccine (PCV) use at full costs as they transition from Gavi support. Using Kenya 34 as a case study we assessed the incremental cost-effectiveness of continuing PCV use.
Introduction
where they were treated: hospitalised cases, cases treated as outpatients and those that did not 148 reach medical care (Table 1) . All costs not referring to 2016 were converted into 2016 US 149 dollars for our analysis by using the International Monetary Fund's (IMF) GDP deflators for 150 Kenya.
152
Disability Adjusted Life Years (DALYs) 153
The treatment costs for the predicted number of cases for the four syndromes considered and 154 the vaccination cost of birth cohorts were estimated and used to calculate the costs per 155 disability-adjusted-life-year (DALY) averted. The years lost due to disability (YLD) were 156 calculated as the product of disease incidence, duration of disease and disability weights. We the epidemiological mode with a probabilistic sensitivity analysis of the costing model (Table  analyses either with or without accounting for hyporesponsiveness. In the base case, we vaccine efficacy was estimated separately in vaccine-type carriers and in others. We also case) or discounting costs alone.
181

Results
182
Model fit and predicted IPD incidence 183 There was good agreement between the observed and fitted age-group and serotype-group 184 specific carriage prevalence (Figure 1 & Appendix) and IPD incidence ( Figure 2 ). If cohorts 185 of children born after the start of year 2022 are no longer vaccinated with PCV, the model 186 predicts that IPD incidence will bounce back from 8.5, in 2022 to 16.2 per 100,000 per year 187 in 2032 equalling pre PCV levels ( Figure 3 ). Continuing with PCV is predicted to result in 188 additional small reductions in IPD incidence to 7.9 per 100,000 per year in 2032, and to avert 189 15, 355 (PI: 10, 125) deaths and 112, 050 (PI: 79, 981) from the vaccination of previous cohorts for some of the study period with gradually 199 declining impact on IPD incidence. As a result, we predict that continuation of PCV will not 200 be cost effective initially. However, we show that within only one year after the decision to 201 continue PCV the incremental cost-effectiveness ratio (ICER), in comparison to discontinuing 202 PCV, improves substantially towards the threshold of the Kenyan GDP per capita ($1455 in 203 2016) and continues to improve throughout the study period ( Figure 3 ). Compared to 204 discontinuing PCV in 2022, we predicted that, in 2032, the cost per DALY averted is $142, 205 the cost per case averted $876 and the cost per death averted $6366 (Table 2) .
207
Sensitivity analyses 208 Using the Kenyan GDP per capita of $1455 in 2016 as a threshold to determine cost 209 effectiveness, all posterior samples indicated that continuation of PCV vaccination is cost 210 effective no more than six years after 2022. Compared to discounting both costs and DALYs, 211 discounting costs alone resulted in an ICER that was twice as favourable (Table 2) .
213
We estimate that the effect of hyporesponsiveness is relatively small. Vaccine serotype 214 carriers had a vaccine efficacy estimate against carriage that was 4 percentage points lower 215 than that for other vaccinees (Appendix, table A1). Hence omitting this mechanism in the 216 model structure led to similar results (Supplementary Figure 3) . Therefore, we did not include 217 hyporesponsiveness in our final model.
219
Discussion
220
In the near future Kenya, like several other low income countries, will be expected to take 221 over the full cost of the national pneumococcal conjugate vaccination procurement. In this 222 study, we have estimated the cost-effectiveness of continuing PCV using Gavi's schedule of proportion of cases that get hospital treatment would mean that the overall costs of treatment 285 were overestimated while the fatal cases, and therefore DALYs, were underestimated. The 286 overall effect would be an overestimated ICER, which is conservative. In our analysis, we 287 estimated the proportion of cases that were hospitalized using local surveillance data.
288
However, we did not have local information on what proportion among non-hospitalised 289 cases are treated as outpatients; this was obtained from a Ugandan verbal autopsy study 290 among fatal pneumonia cases 20 . It is possible, therefore, that we have overestimated the 291 number of patients among non-hospitalised treated as outpatients, and, by extension, 292 overestimated the ICER.
294
Several low-income countries will soon be transitioning out of Gavi support and will need to 295 decide whether to sustain their pneumococcal conjugate vaccination. We demonstrate, using 296 Kenya as an example, how ongoing detailed surveillance can be combined with mathematical 297 modelling and health economics to inform an upcoming decision of a country's National
298
Immunization Technical Advisory Group (NITAG) on the cost-effectiveness of different 299 policy options. We estimate that maintaining PCV is essential to sustain the decreased burden 300 of pneumococcal disease and that it is cost-effective against conventional criteria. However,
301
to afford PCV vaccination in the post-Gavi era, Kenya will need to substantially increase the 302 proportion of health spending on routine immunization. 
Accelerated transition phase:
Contribution starts at an additional 20% of the difference between the projected price of the vaccine in the year a country enters fully selffinancing phase and the co-financing amount per dose paid in the preceding year, and increases linearly over four years to reach the projected price. !) . The acquisition rates from the single to multiple serotype carriage states are reduced by competition parameters denoted by ! with two subscripts; the first denoting the serotype group (!, ! !"# !, for VT, strong NVT and weak NVT respectively) of the resident serotypes and the second denoting the age-group. The competition parameters have two sets of values, one for age group <6 and another for age group ≥6 years (see Appendix). The age-group specific VT, weak NVT and strong NVT clearance rates are denoted by r !" , r !"# and r !"# , respectively. In addition to the transitions between the 14 epidemiological states as shown in the Figure, individuals die from any states at age-specific death rates and new individuals are born into the completely susceptible state.
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Supplementary Figure 3: Model structure flow diagram including hyporesponsiveness
The epidemiological states include individuals that are susceptible (non-carrying), !; carry a vaccine serotype, !; carry a weak non-vaccine serotype, ! ! ; carry a strong non-vaccine serotype, ! ! ; carry simultaneously a weak and a strong non-vaccine serotype, ! !" ; carry simultaneously a vaccine serotype and a weak non-vaccine serotype, ! ! ; or carry simultaneously a vaccine serotype and a strong non-vaccine serotype, ! ! (see text). Once vaccinated, individuals not carrying vaccine serotypes move to the corresponding states (S (!) ,N ! (!) , N ! (!) , N !" (!) ) while those carrying vaccine serotypes (V, B ! (!) , B ! (!) ) move to the corresponding hyporesponse-associated states (ℎV, ℎB ! (!) , ℎB ! (!) ) The acquisition rates from the single to multiple serotype carriage states are reduced by competition parameters denoted by ! with two subscripts; the first denoting the serotype group (!, ! !"# !, for VT, strong NVT and weak NVT respectively) of the resident serotypes and the second denoting the agegroup. The competition parameters have two sets of values, one for age group <6 and another for age group ≥6 years (see Appendix). The age-group specific VT, weak NVT and strong NVT clearance rates are denoted by r !" , r !"# and r !"# , respectively. In addition to the transitions between the 21 epidemiological states as shown in the Figure, individuals die from any states at age-specific death rates and new individuals are born into the completely susceptible state.
Appendix: Model structure and parameters estimates
Model structure
A more detailed description of the model and the likelihood function is presented in 1 . The brief description provided in this appendix is to help in the understanding of the notation used, without necessarily referring to 1 . The model is compartmental, age-structured and dynamic. Compartments are defined according to pneumococcal carriage states ( Supplementary Figure 2) . It has a Susceptible-Infected-Susceptible (SIS) structure for three serotype groups: the PCV10 serotypes, strong NVT and weak NVT. Figure 3) .
Parameterisation
A susceptible unvaccinated individual in age group i becomes colonised with VTs, strong NVTs or weak NVTs at age-group-specific time-dependent rates (forces of infection) denoted by λ !" (t), λ !"# (t) and λ !"# (t), respectively. The forces of infection were expressed as functions of the social mixing matrix and age-group specific factors (q ! ) that scale the rate of social contacts into infectious contacts. Due to competition between serotypes in colonising the nasopharynx, the acquisition rate of a secondary serotype is lower than the acquisition rate of that serotype in a completely susceptible individual. Three competition parameters, c !" , c !" and c !" , represent the fraction by which acquisition rates of secondary serotypes are reduced in <6 year olds infected with VTs, weak NVTs and strong NVTs, respectively. Two competition parameters, c !" = c ! = c ! and c ! , were used for individuals aged ≥ 6 years infected with VTs/weak NVTs and strong NVTs, respectively. In the vaccinated compartments the rate of acquisition of VTs are reduced by the vaccine efficacy against carriage acquisition denoted !, or ! ! according to whether the compartment is associated with hyporesponsiveness.
The Metropolis-Hastings algorithm was used to draw samples from the posterior distributions of the parameters. Uniform priors in the range 0-1 were used for competition parameters and the social contact scaling parameters (q ! ). For the vaccine efficacy parameters we used a normal prior centered around 50% with 95% uncertainty interval of 40-60%. 50,000 adaptive MCMC iterations were used. After a burn-in of 25,000 was discarded the remaining stationary samples were thinned to 5000 to estimate the posterior distribution. Convergence was assessed graphically, by observing was no negative or positive trend (zero gradient) in the chain, and by using Geweke diagnostic to check if a chain was stationary. The thinned posterior samples of the parameters were summarised to obtain point estimates (posterior mean) and probability (credibility) intervals. The parameter estimates are shown in Table A1 .
